Shield Therapeutics Plc (STX.L), a company focused on iron deficiency, said on Monday that it has appointed Anders Lundstrom as Chief Executive Officer with effect from February 1.
Lundstrom, who joined the Board in 2021 and was appointed as interim CEO on July 24, 2024, after then CEO Greg Madison decided to leave the company.
For comments and feedback: editorial@rttnews.com